The World Health Organisation (WHO) has issued a public alert concerning the circulation of fake diabetes medications that have been in the market since 2022 which has affected every part of the world’s.
The health organization, in a declaration, specifically mentioned issues with these fake drugs in the United Kingdom, the United States, and Brazil starting in October 2023.
This current issues involves Ozempic which is a drug that includes the active ingredient semaglutide, which is also sanctioned in the EU for treating type 2 diabetes.
WHO mentioned that the fake version is an exact replica of the genuine drug. Since it also reduces appetite, it’s being increasingly used for weight reduction.
However, the fake medications may not have the right amount of dosage of active ingredients which can lead to uncontrolled blood sugar levels in diabetics and could also contain ingredients that are harmful to the health.
The WHO urged healthcare professionals, pharmacists, regulatory bodies, and the general public to stay alert.
They also advised that individuals should only purchase medications with a prescription from brick-and-mortar pharmacies, not online.
Patients should ensure that they check that the insulin pen’s dosage markings are clear, the label is accurate, and there are no typos on the packaging.
